Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Neuroblastoma 3Medulloblastoma 2Carcinoid Tumor 2von Hippel-Lindau Disease 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Prostatic Neoplasms 1Parathyroid Neoplasms 1Paraganglioma 1Multiple Endocrine Neoplasia 1Hypoglycemia 1Hyperparathyroidism 1Hypercalcemia 1Cancer Diagnosis 1

Interventions

tanespimycin 1gallium Ga 68 dotatate 1Sunitinib 1PT2385 1Oxygen-15 1Fluorodeoxyglucose F18 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × von Hippel-Lindau Disease × gallium Ga 68 dotatate × Clear all
NCT01967537 2019-11-19

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
341 enrolled 14 charts
EndocrineNET

von Hippel-Lindau Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡